Dr. Klein named to the Board of Directors of the American Academy of Neurology
Abington Neurological Associates is pleased to announce Dr. Klein has been appointed as Chair of the Medical Economics and Practice committee as well as serving on the Board of Directors of the American Academy of Neurology, the largest organization for neurology worldwide.
Click here for more information:
ANA Clinical Research Center: Alzheimer's Newsletter May 2019
We continue to fight for a disease modifying treatment in Alzheimer's disease despite recent setbacks.
Dr. David C. Weisman, MD
In tragic news, two recent Alzheimer trials have been halted for futility. In both cases, the study drug was a monoclonal antibody directed against b-amyloid, the toxic protein fragment which appears to cause Alzheimer's. So why did it fail? One reason may be that this hypothesis—that amyloid causes the disease—may be therapeutically wrong. (It may remain correct as a necessary cause, but removing the cause later in the disease will not help). If this is the case, then removing amyloid will not change the disease. But there are reasons to think that these drugs failed and hope other similar mechanisms can succeed.
This trial joins a field of other trials investigating anti-amyloid antibodies, some ongoing, some negative, and one positive. Full comprehension is impossible given the limited data, and we should learn to suspend judgement until we have a complete picture. So far, we don't have answers to important questions: do differences in the monoclonal antibodies, their target epitope, their spine, their dosages, their titration schedule? What is an appropriate time course to measure this slow-moving disease? Is a 1.5- to 2-year trial not long enough? Was there too much symptomatic ARIA (leaky vessels giving rise to swelling in the brain) despite titration? A few cases of symptoms from this swelling could have dragged treatment group down. What relevant species of amyloid oligomers and protofibrils should be targeted for removal? One of the trials used a functional endpoint of CDR-SOB, which is a hard one to move. This metric is difficult and was barely changed between groups on the single positive mab trial with BAN (see slide 14 from the slideshow linked below).
Were the populations too mild or non-progressive? Did the placebo do too well? Was CDR preserved in early disease?
Yes, let's keep multiple lines of inquiry alive. Tau drugs look promising. As does polytherapy, neuroprotectives. Let's never give up. But let's fully know that we hit the target, right drug, right pharmakokinetics, in the right people, right stage, using the right metrics before giving up. I realize it is easy to say, hard to do, but patients deserve it. More data will come.
Thanks to all investigators, the teams at Biogen, and the subjects who put their lives on the line. All heroes, the subjects most of all, and deserve our deepest admiration.
I was a small piece in the search to find a cure. Now I feel as if I'm getting erased, and medical science doesn't have any answers.
Dr. Klein publishes new Op Ed in The Inquirer
Dr. Weisman quoted in Philly.com regarding the dangers of 23 and Me genetic testing
Congratulations to our Top Doctors!
30 year old stroke survivor recalls the scariest day of her life!
Read Christie Flemming's amazing story here.
Tackling Concussions in Youth Football. Are Children Safe?
See Dr. Weisman discuss the recent article from Wake Forest University that demonstrates brain injury without concussion in children playing football.
Abington Physician featured on CBS News discussing new trial for people suffering from dementia
Dr. David Weisman featured on CBS news discussing a new clinical trial for Lewy Body Dementia.
Abington Neurologist discusses the future of Alzheimer's on NBC 10.
Abington Neurological Associate's Dr. David Weisman sits down with NBC10’s Keith Jones to discuss the effects Alzheimer’s Disease has and the NOBLE clincal trial.
Abington Neurological Associates physician recognized for work in Alzheimer's Disease
The Alzheimer's Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California San Diego. The ADCS is a major initiative for Alzheimer's disease (AD) clinical studies in the Federal government, addressing treatments for both cognitive and behavioral symptoms. This is part of the NIA Division of Neuroscience program's effort to facilitate the discovery, development and testing of new drugs for the treatment of AD and also is part of the Alzheimer's Disease Prevention Initiative. Dr. David Weisman of Abington Neurological Associates was recognized as an investigator in this important effort.
New treatments offer unique opportunities to treat Alzheimer’s Disease
Abington Neurologist discusses biosimilars and biologics in the Philadelphia Business Journal
Biosimilars are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of controlled gene expression.
Physicians should be made aware if pharmacies chose to switch a physician prescribed biologic product for a biosimilar. Read the op-ed article in the Philadelphia Business Journal.
Abington Memorial Hospital is given the elite status of being a Comprehensive Stroke Center.
Abington Neurological Associates physicians help Abington Memorial Hospital to become designated a comprehensive stroke center – a certification earned by fewer than 1 percent of hospitals nationwide.
As the first Pennsylvania stroke center to earn the highly regarded Gold Seal of Approval from the Joint Commission, AMH consistently earns awards that distinguish itself in the Philadelphia region for its stroke services.
These honors include the American Stroke Association/American Heart Association’s Gold Plus Performance Achievement Award for stroke quality-of-care.
Dr. Dan Gzesh is proud to serve as the director of this center, known as the Diamond Stroke Center.
Abington Neurological Associates physician testifies on behalf of physicians and patients before the Pennsylvania House of Representatives
Abington Neurological Associates physician testifies before the House of Representatives in Harrisburg, PA regarding House Bill 746 that addresses biosimilar medications.
Biosimilars are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods.
In short, this bill ensures that patients and physicians are made aware if the pharmacist substitutes a biosimilar product.
For further information, please click to see the Pennsylvania Medical Society update.
Abington Neurological Associates physician serves as co-author on national expert panel publication in headache
Abington Neurological Associates physician is co-author of an seminal expert consensus article in the academic journal, Headache, reviewing nerve blocks for headache disorders.
Please click for details.
Abington Neurological Associates physician is again named “Top Doc” by Philadelphia Magazine
Abington Neurological Associates physician is once again named Top Doc by Philadelphia Magazine for 2013.